Turbine, a leading developer of cell simulations with AI, announced a research collaboration with MSD (the tradename of Merck & Co., Inc., Rahway NJ USA) to create simulations of cancer patient populations that remain difficult to treat and study in laboratory settings.
To develop novel treatments for patients, scientists must first understand the biological mechanisms driving their cancer in wet lab experiments. Laboratory models of many solid tumors fail to reflect the molecular diversity and biological complexity observed in patients. Many of these cancers depend on biological pathways and microenvironmental conditions that cannot be replicated in standard lab cultures, limiting the discovery of effective therapies.
Also Read: BioDuro & Atombeat Launch AI Platform for Peptide Discovery
Under the agreement, MSD will use Turbine’s Simulated Cells™ to create virtual tumor models that closely mirror disease subtypes which remain difficult to study in pre-clinical experiments and thus hard to treat. Across millions of simulated experiments, the parties hope to uncover novel dependencies in these highly resistant tumor populations, guiding MSD’s wet lab experimental efforts to validate novel drug targets, biomarkers and rational combination therapies. The collaboration is initially set for one year, after which time MSD will have the option to obtain multi-year access to Turbine’s virtual lab and proprietary virtual tumor models.
“Millions of cancer patients are fighting forms of the disease for which no lab-based model exists today,” said Daniel Veres, Chief Scientific Officer at Turbine. “Unconstrained by the physical limitations of lab-based tumor models, the promise of Simulated Cells™ is to mimic the biology of disease in patients and open new paths to treat them. It’s great to get a chance to make this possible with an organization committed to rethinking the R&D process with AI.”
Source: PRNewswire
